Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company's Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals
Portfolio Pulse from
Tonix Pharmaceuticals has announced a peer-reviewed publication in the mSphere Journal, highlighting the tolerability of its single-dose Mpox and Smallpox vaccine candidate, TNX-801, in immune-compromised animals. This comes as the WHO declares the spread of a new Clade Ib Mpox a public health emergency of international concern.
November 13, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals' TNX-801 vaccine candidate has shown tolerability in immune-compromised animals, as published in the mSphere Journal. This development is timely given the WHO's declaration of a new Mpox strain as a public health emergency.
The publication of TNX-801's tolerability in a peer-reviewed journal is a positive development for Tonix Pharmaceuticals, especially in light of the WHO's declaration of a new Mpox strain as a public health emergency. This could increase interest and investment in TNXP, potentially driving the stock price up.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90